1
|
Fett T, Zecchinon L, Vanden Bergh P, Desmecht D. Mannheimia haemolytica leukotoxin-induced cytolysis of caprine (Capra hircus) leukocytes is mediated by the CD18 subunit of beta2-integrins. Microb Pathog 2008; 45:337-42. [PMID: 18775487 DOI: 10.1016/j.micpath.2008.08.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2008] [Revised: 07/23/2008] [Accepted: 08/06/2008] [Indexed: 11/16/2022]
Abstract
Mannheimiosis is the major respiratory disease among some ruminants, whereas it is not pathogenic for other mammals, an observation that has been attributed to a specific interaction between Mannheimia haemolytica leukotoxin (Lkt) and bovine or ovine CD18 subunit of lymphocyte function-associated antigen-1 (LFA-1) and Mac-1. We therefore hypothesized that Lkt utilizes CD18 as its receptor on caprine leukocytes as well. We have transiently transfected the beta2-integrins-deficient K-562 cell line with cDNAs encoding caprine CD11a and caprine CD18 to determine the susceptibility of the transfectants to Lkt-induced cytolysis. Flow cytometric analysis of the transfectants revealed surface expression of caprine LFA-1 and lysis by Lkt in a concentration-dependent manner whereas the parent cells were not. Moreover, K562 cells expressing caprine CD18 and human or bovine CD11a were also sensitive to Lkt whereas K-562 cells expressing caprine CD11a and human CD18 were not. Taken together, these results indicate that CD18 on caprine leukocytes serves as a receptor for Lkt.
Collapse
Affiliation(s)
- T Fett
- Department of Pathology, Faculty of Veterinary Medicine, University of Liege, FMV Sart Tilman B43, B-4000 Liege, Belgium
| | | | | | | |
Collapse
|
4
|
Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Bergh PV, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 2006; 94:904-13. [PMID: 16508639 PMCID: PMC2361366 DOI: 10.1038/sj.bjc.6603003] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Mucinous epithelial ovarian cancers (MOC) are clinically and morphologically distinct from the other histological subtypes of ovarian cancer. To determine the genetic basis of MOC and to identify potential tumour markers, gene expression profiling of 49 primary ovarian cancers of different histological subtypes was performed using a customised oligonucleotide microarray containing >59 000 probesets. The results show that MOC express a genetic profile that both differs and overlaps with other subtypes of epithelial ovarian cancer. Concordant with its histological phenotype, MOC express genes characteristic of mucinous carcinomas of varying epithelial origin, including intestinal carcinomas. Differences in gene expression between MOC and other histological subtypes of ovarian cancer were confirmed by RT–PCR and/or immunohistochemistry. In particular, galectin 4 (LGALS4) was highly and specifically expressed in MOC, but expressed at lower levels in benign mucinous cysts and borderline (atypical proliferative) tumours, supporting a malignant progression model of MOC. Hence LGALS4 may have application as an early and differential diagnostic marker of MOC.
Collapse
Affiliation(s)
- V A Heinzelmann-Schwarz
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
- Division of Gynecology, University Hospital Zurich, Switzerland
| | - M Gardiner-Garden
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
| | - S M Henshall
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
| | - J P Scurry
- South Eastern Area Laboratory Service, Prince of Wales Hospital, Randwick, NSW 2031, Australia
| | - R A Scolyer
- Department of Anatomical Pathology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
| | - A N Smith
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
| | - A Bali
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
| | - P Vanden Bergh
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
| | - S Baron-Hay
- Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW 2065, Australia
| | - C Scott
- Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW 2065, Australia
| | - D Fink
- Division of Gynecology, University Hospital Zurich, Switzerland
| | - N F Hacker
- Gynaecological Cancer Centre, Royal Hospital for Women, Randwick, NSW 2031, Australia
| | - R L Sutherland
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
| | - P M O'Brien
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
- Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
| |
Collapse
|